The short version

From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.

  • Tempus AI is the larger company, worth $12.0B, about 1.5 times HealthEquity.
  • Tempus AI grew revenue faster over the last year (+21.6% vs +7.6%).
  • HealthEquity keeps more of each dollar of revenue as operating profit (25.8% vs -19.8%).

Side by side

The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.

MeasureHQYTEM
Market cap$8.3B$12.0B
Share price$92.61$70.35
Revenue (last fiscal year)$1.3B$1.3B
Free cash flow (last fiscal year)$409M-$239M
Revenue growth, last year+7.6%+21.6%
Revenue growth per year, last 5 fiscal years+14.8%+58.3%
Operating margin25.8%-19.8%
Net margin17.4%-17.8%
Return on equity11.9%-57.2%
P/E (trailing)40.1x—
Price / free cash flow18.2x—
EV / EBITDA17.3x—
FCF growth the price implies5.2%—
Dividend yield——
Debt / equity0.64x4.32x
Fundamental gradeBF
Superinvestors holding it43
Insider purchases, last 12 months02

Results from SEC filings

Revenue and free cash flow by fiscal year, from each company's 10-K filings.

HealthEquity

YearRevenueFree cash flowOp. margin
2022$757M$69M-3.2%
2023$862M$102M1.1%
2024$1000M$200M11.8%
2025$1.2B$287M13.5%
2026$1.3B$409M24.6%

Tempus AI

YearRevenueFree cash flowOp. margin
2022$321M-$187M-82.8%
2023$532M-$249M-36.9%
2024$693M-$211M-99.7%
2025$1.3B-$239M-19.9%

Where the revenue comes from

HealthEquity · by products, 2026

Custodial$637M48%
Service$485M37%
Interchange$192M15%

Tempus AI · by products, 2025

Diagnostics$955M75%
Data and applications$316M25%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open HQY in Investingly

Questions

Which is bigger, HealthEquity or Tempus AI?

Tempus AI (TEM), at $12.0B against $8.3B.

Which grows faster, HQY or TEM?

Tempus AI: revenue grew +21.6% over the last year, against +7.6%.

Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.